Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25189591 | 0.89 | DHODH (0.41) | DHODHTSHR | |
| SCHEMBL30687116 | 0.75 | DHODH (0.49) | DHODHTSHRPTK2HCAR2 | |
| SCHEMBL4753717 | 0.73 | HCAR2 (0.44) | DHODHTSHRHCAR2KMT2A | |
| SCHEMBL2575246 | 0.72 | TSHR (0.52) | DHODHTSHRPTK2HCAR2L3MBTL1 | |
| SCHEMBL21612312 | 0.72 | TSHR (0.43) | DHODHTSHRPTK2HCAR2L3MBTL1 | |
| SCHEMBL19768752 | 0.72 | TSHR (0.43) | DHODHTSHRPTK2HCAR2L3MBTL1 | |
| SCHEMBL23774992 | 0.72 | TSHR (0.43) | DHODHTSHRPTK2HCAR2L3MBTL1 | |
| SCHEMBL25217688 | 0.71 | DHODH (0.32) | DHODH | |
| SCHEMBL1220143 | 0.71 | HSD17B10 (0.56) | TSHRKMT2A | |
| SCHEMBL1006964 | 0.69 | DHODH (0.47) | DHODHTSHRHCAR2L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118056817-A | Industrial synthesis method of GS6207 key intermediate | 苏州匠化生物科技有限公司 | 2024-05-21 | — | — | CN | claimed |
| EP-4423069-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-12071411-B2 | Inhibitors of HIF-2α and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-118176183-A | HIF-2 alpha inhibitors and methods of use thereof | 艾库斯生物科学有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118056817-A | Industrial synthesis method of GS6207 key intermediate | 苏州匠化生物科技有限公司 | 2024-05-21 | — | — | CN | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023077046-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023077046-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2729448-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| EP-2408762-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI (FR) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | US | disclosed |
| WO-2010106290-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | DHODH 1574/4885TSHR 1120/4885PTK2 2390/4885 |
| US-12071411-B2 | Inhibitors of HIF-2α and methods of use thereof | HIF1AN, HIF1A, EGLN2 | DHODH 823/4885TSHR 2861/4885PTK2 2098/4885 |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | DHODH 974/4885TSHR 3077/4885PTK2 2128/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | DHODH 248/4885TSHR 4824/4885PTK2 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.